Table 5 Canonical pathway analysis of the constructed interaction networks in primary and metastatic prostate cancer
Canonical pathway analysis | p-value (<0.05) |
|---|---|
Primary prostate cancer | Â |
Pathways in cancer | 1.70e-03 |
Rb1 pathway | 5.95e-03 |
Retinoic acid pathway | 6.61e-03 |
Aurora A pathway | 7.44e-03 |
Beta-catenin degradation pathway | 9.95e-03 |
Wnt/beta-catenin pathway | 1.03e-02 |
Wnt canonical signaling pathway | 1.34e-02 |
Met pathway (signaling of HGF receptor) | 1.39e-02 |
P38-alpha/beta downstream pathway | 1.52e-02 |
Beta-catenin nuclear pathway | 1.58e-02 |
Aurora B pathway | 1.66e-02 |
EPHB forward pathway | 1.81e-02 |
IFN-gamma pathway | 1.81e-02 |
P53 hypoxia pathway | 1.97e-02 |
MYC repress pathway | 2.15e-02 |
Progesterone mediated oocyte maturation | 2.19e-02 |
Rac CycD pathway (Ras and Rho protein on G1/S transition) | 2.73e-02 |
PLK1 pathway | 2.88e-02 |
IL-6 (interleukin-6) pathway | 3.08e-02 |
FGFR2C ligand binding and activation | 3.58e-02 |
Cell cycle | 4.43e-02 |
PDGFR-beta signaling pathway | 4.59e-02 |
Metastatic prostate cancer | Â |
MYC activate pathway | 1.41e-04 |
ErbB network pathway | 2.78e-03 |
KIT receptor signaling pathway | 3.28e-03 |
IL-10 pathway | 4.40e-03 |
Pathways in cancer | 4.76e-03 |
ErbB4 pathway | 6.12e-03 |
Her2 pathway (ErbB2 in signal transduction and oncology) | 8.51e-03 |
Yap1 and Wwtr1/Taz stimulated gene expression | 1.09e-02 |
Smooth Muscle Contraction | 1.22e-02 |
Barrestin pathway | 1.53e-02 |
IL-6 signaling pathway | 1.85e-02 |
STAT3 pathway | 1.85e-02 |
IL-2/STAT5 pathway | 2.00e-02 |
RAS pathway | 2.00e-02 |
ErbB2/ErbB3 signaling pathway | 2.19e-02 |
Syndecan4 pathway | 2.38e-02 |
PPAR-alpha pathway | 2.61e-02 |
Integrin signaling pathway | 3.72e-02 |
Rela pathway | 3.78e-02 |
HDAC class I pathway | 3.94e-02 |
FOXM1 pathway | 4.24e-02 |
IL-7 pathway | 4.23e-02 |
EGFR pathway | 4.70e-02 |